Analyst Price Target is $4.00
▲ +312.29% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for VolitionRx in the last 3 months. The average price target is $4.00, with a high forecast of $6.00 and a low forecast of $2.00. The average price target represents a 312.29% upside from the last price of $0.97.
Current Consensus is
The current consensus among 2 investment analysts is to buy stock in VolitionRx. This Buy consensus rating has held steady for over two years.
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company is based in Henderson, Nevada.